Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. Molecular Medicine / 分子醫學研究所
  4. SHP-1/STAT3-related signaling pathway in HCC targeting therapy
 
  • Details

SHP-1/STAT3-related signaling pathway in HCC targeting therapy

Date Issued
2012
Date
2012
Author(s)
Tai, Wei-Tien
URI
http://ntur.lib.ntu.edu.tw//handle/246246/247377
Abstract
Abstract Human hepatocellular carcinoma (HCC) is the fifth most prevalent solid tumor in the world and the fourth main inducer of cancer-related death. Surgical resection, the only curative treatment for HCC, is feasible in only 20-30% of the patients at diagnosis. Unfortunately, systemic chemotherapy or liver transplantation is limited for patients with HCC. In 2007, sorafenib (NexavarR), a multiple kinase inhibitor, has shown survival benefits in patients with advanced HCC and become the first clinically approved drug for HCC. First, we have showed that sorafenib sensitizes HCC cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) through the inhibition of signal transducer and activator of transcription 3 (STAT3) (Chapter 1). In this study, we found that sorafenib inhibits STAT3 through up-regulating the activity of Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1), a protein tyrosine phosphatase and a key inhibitory regulator of STAT3, in HCC cells. To examine whether sorafenib’s effect on STAT3 is related to its kinase inhibitory activity, we further generated a series of sorafenib derivatives which lack activities on kinases. Interestingly, we have observed SC-1, a sorafenib derivative which is close to sorafenib structurally but no kinase activity, showed even better in vivo activity than sorafenib in HCC tumors. These results suggest that SHP-1-dependent STAT3 inhibition is a major kinase-independent target of sorafenib (Chapter 2). In addition to sorafenib, we also found that dovitinib, another multiple kinase inhibitor, shows the anti-HCC effect via a SHP-1/STAT-dependent signaling pathway and overcomes the resistance of sorafenib (Chapter 3). Finally, to elucidate the molecular mechanism by which sorafenib increases SHP-1 phosphatase activity, we demonstrated the conformation-based changes in SHP-1 to promote catalytic activity after sorafenib treatment (Chapter 4). Sorafenib increases SHP-1 activity in vitro and in vivo, indicating that sorafenib affects phosphatase activity directly. Based on a series of deletion mutants of SHP-1, we observed that N-terminal SH2 domains (N1) strongly involved in sorafenib-induced STAT3 inhibition and apoptotic effect. Moreover, D61, a critical residue in N1 responsible to form inhibitory salt bridge with catalytic domain, also abrogates the biological effect of sorafenib. In co-IP experiments, sorafenib impairs the interaction between N1 and PTP directly. Furthermore, the role of elevated SHP-1 served as tumor suppressor of HCC was confirmed in cells expressed constitutively activate mutant (dN1 and D61A). Together, we propose a conformational change model for sorafenib-induced SHP-1 activity. Sorafenib potentially opened the inhibited structure of SHP-1 through impairing the linkage between N-SH2 and PTP domains to increase phosphatase activity.
Subjects
HCC
Sorafenib
targeting therapy
Dovitinib
STAT3
SHP-1
SDGs

[SDGs]SDG3

Type
thesis
File(s)
Loading...
Thumbnail Image
Name

index.html

Size

23.27 KB

Format

HTML

Checksum

(MD5):32d418c87987c7e5bdde22d2f7136759

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science